Bone Biologics Q2 EPS Estimate Lowered by Zacks Small Cap

Bone Biologics Co. (NASDAQ:BBLG) – Stock analysts at Zacks Small Cap lowered their Q2 2025 earnings per share (EPS) estimates for Bone Biologics in a research note issued to investors on Wednesday, June 11th. Zacks Small Cap analyst B. Sorensen now anticipates that the company will post earnings per share of ($1.93) for the quarter, down from their previous estimate of ($1.92). The consensus estimate for Bone Biologics’ current full-year earnings is ($5.00) per share. Zacks Small Cap also issued estimates for Bone Biologics’ Q3 2025 earnings at ($1.79) EPS, Q4 2025 earnings at ($1.66) EPS, FY2025 earnings at ($7.30) EPS and FY2026 earnings at ($5.81) EPS.

Bone Biologics Stock Performance

Bone Biologics stock opened at $4.74 on Monday. Bone Biologics has a 1-year low of $3.42 and a 1-year high of $25.50. The stock’s fifty day moving average is $4.51 and its two-hundred day moving average is $5.43.

Bone Biologics (NASDAQ:BBLG) last announced its quarterly earnings data on Monday, May 12th. The company reported ($1.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.88) by $0.96.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.